Long-acting injectable (LAI) is a kind of pharmaceutical for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication. Rather than the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two to four weeks intervals.

Market Analysis and Insights: Global Long-Acting Injectables Market
The global Long-Acting Injectables market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Long-Acting Injectables market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Long-Acting Injectables market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Long-Acting Injectables market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Long-Acting Injectables market.

Global Long-Acting Injectables Scope and Market Size
Long-Acting Injectables market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Long-Acting Injectables market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Small and Middle Sized Molecule
Large Sized Molecule

Segment by Application
Schizophrenia
Other Psychotic Disorders

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eli Lilly
Pfizer
GlaxoSmithKline
Johnson & Johnson
Lupin
Zogenix
DURECT
Medincel